From Wikipedia, the free encyclopedia
Glutaminolysis is a series of biochemical
reactions by which the amino acid glutamine is degraded to glutamate, aspartate, CO2, pyruvate,
lactate, alanine and citrate.[1][2][3][4][5][6][7][8][9][10][11][12][13
][14][15][16][17][18][19][20
]
The
glutaminolytic pathway
Glutaminolysis partially recruits reaction steps from the citric acid
cycle and the malate-aspartate shuttle.
Reaction
steps from glutamine to α-ketoglutarate
The conversion of the amino acid glutamine to α-ketoglutarate takes place in two reaction
steps:
Conversion of glutamine to α-ketoglutarate
1. Hydrolysis of the amino group of glutamine yielding glutamate
and ammonium. Catalyzing
enzyme: glutaminase
(EC 3.5.1.2)
2. Glutamate can be excreted or can be further metabolized to
α-ketoglutarate.
For the conversion of glutamate to α-ketoglutarate three
different reactions are possible:
Catalyzing enzymes:
Recruited reaction steps of the citric acid cycle and malate
aspartate shuttle
The glutaminolytic pathway. Figure legend: blue color = reaction
steps of the citric acid cycle; brown color = reaction steps of the
malate aspartate shuttle; green color = enzymes overexpressed in
tumors. 1 = glutaminase, 2 = GOT, 3 = α-ketoglutarate
dehydrogenase, 4 = succinate dehydrogenase, 5 = fumarase, 6 =
malate dehydrogenase, 7a = cytosolic malic enzyme, 7b =
mitochondrial malic enzyme, 8 = citrate synthase, 9 = aconitase, 10
= lactate dehydrogenase
- α-ketoglutarate + NAD+ + CoASH →
succinyl-CoA + NADH+H+ + CO2
catalyzing enzyme: α-ketoglutarate dehydrogenase complex
- succinyl-CoA + GDP + Pi → succinate +
GTP
catalyzing enzyme: succinyl-CoA-synthetase, EC 6.2.1.4
- succinate + FAD → fumarate +
FADH2
catalyzing enzyme: succinate dehydrogenase, EC
1.3.5.1
catalyzing enzyme: fumarase, EC 4.2.1.2
- malate + NAD+ → oxaloacetate + NADH +
H+
catalyzing enzyme: malate dehydrogenase, EC 1.1.1.37
(component of the malate aspartate shuttle)
- oxaloacetate + acetyl-CoA + H2O → citrate +
CoASH
catalyzing enzyme: citrate synthase, EC 2.3.3.1
Reaction
steps from malate to pyruvate and lactate
The conversion of malate to pyruvate and lactate is catalyzed
by
- NAD(P) dependent malate decarboxylase (malic enzyme; EC
1.1.1.39 and 1.1.1.40) and
- lactate dehydrogenase (LDH; EC
1.1.1.27)
according to the following equations:
- malate + NAD(P)+→ pyruvate + NAD(P)H +
H+ + CO2
- pyruvate + NADH + H+ → lactate +
NAD+
Intracellular compartmentalization of the glutaminolytic
pathway
The reactions of the glutaminolytic pathway take place partly in
the mitochondria and to some extent in the cytosol (compare the
metabolic scheme of the glutaminolytic pathway).
Glutaminolysis:
an important energy source in tumor cells
Glutaminolysis takes place in all proliferating cells, such as
lymphocytes, thymocytes, colonocytes,
adipocytes and especially in tumor cells.[1][2][3][4][5][6][7][8][10][11][12].[13
][14][16][18][19][21]
In tumor cells the citric acid cycle is truncated due to an
inhibition of the enzyme aconitase (EC 4.2.1.3) by high concentrations
of reactive oxygen species
(ROS)[22][23]
Aconitase catalyzes the conversion of citrate to isocitrate. On the
other hand tumor cells over express phosphate dependent glutaminase
and NAD(P)-dependent malate decarboxylase,[9][24][25][26][27] which
in combination with the remaining reaction steps of the citric acid
cycle from α-ketoglutarate to citrate impart the possibility of a
new energy producing pathway, the degradation of the amino acid
glutamine to glutamate, aspartate, pyruvate CO2, lactate
and citrate.
Besides glycolysis
in tumor cells glutaminolysis is another main pillar for energy
production. High extracellular glutamine concentrations stimulate
tumor growth and are essential for cell transformation.[26][28] On
the other hand a reduction of glutamine correlates with
phenotypical and functional differentiation of the
cells.[29]
Energy
efficacy of glutaminolysis in tumor cells
- one ATP by direct phosphorylation of
GDP
- two ATP from oxidation of FADH2
- three ATP at a time for the NADH + H+ produced
within the α-ketoglutarate dehydrogenase reaction, the malate
dehydrogenase reaction and the malate decarboxylase reaction.
Due to low glutamate dehydrogenase and glutamate pyruvate
transaminase activities, in tumor cells the conversion of glutamate
to alpha-ketoglutarate mainly takes place via glutamate
oxaloacetate transaminase.[5][30]
Advantages of
glutaminolysis in tumor cells
- Glutamine is the most abundant amino acid in the plasma and an
additional energy source in tumor cells especially when glycolytic
energy production is low due to a high amount of the dimeric form of
M2-PK.
- Glutamine and its degradation products glutamate and aspartate
are precursors for nucleic acid and serine synthesis.
- Glutaminolysis is insensitive to high concentrations of
reactive oxygen species (ROS).
- Due to the truncation of the citric acid cycle the amount of acetyl-CoA infiltrated in
the citric acid cycle is low and acetyl-CoA is available for de
novo synthesis of fatty acids and cholesterol. The fatty acids can be used
for phospholipid synthesis or can be released.[31]
- Fatty acids represent an effective storage vehicle for
hydrogen. Therefore, the release of fatty acids is an effective way
to get rid of cytosolic hydrogen produced within the glycolytic glyceraldehyde
3-phosphate dehydrogenase (GAPDH; EC 1.2.1.9) reaction.[32]
- Glutamate and fatty acids are immunosuppressive. The release of
both metabolites may protect tumor cells from immune attacks.[33][34][35]
- It has been discussed that the glutamate pool may drive the
endergonic uptake of other amino acids by system ASC.[17]
See also
citric
acid cycle, malate-aspartate shuttle
References
- ^ a
b
Krebs, HA; Bellamy D (1960). "The
interconversion of glutamic acid and aspartic acid in respiring
tissues". Biochem. J. 75: 523–529. PMID 14411856.
- ^ a
b
Reitzer, LJ; Wice BM and Kennell D
(1979). "Evidence that glutamine, not sugar, is the major energy
source for cultured HeLa-cells". J. Biol. Chem.
254: 2669–2676. PMID 429309.
- ^ a
b
Zielke, HR; Sumbilla CM, Sevdalian
DA, Hawkins RL and Ozand PT (1980). "Lactate: a major product of
glutamine metabolism by human diploid fibroblasts". J. Cell.
Physiol. 104: 433–441. doi:10.1002/jcp.1041040316. PMID 7419614.
- ^ a
b
Mc Keehan, WL (1982). "Glycolysis,
glutaminolysis and cell proliferation". Cell Bio. Int.
Rep. 6: 635–650. doi:10.1016/0309-1651(82)90125-4. PMID 6751566.
- ^ a
b
c
Moreadith RW; Lehninger AL (1984).
"The pathways of glutamate and glutamine oxidation by tumor cell
mitochondria". J. Biol. Chem. 259:
6215–6221. PMID 6144677.
- ^ a
b
Zielke, HR; Zielke CL and Ozand PT
(1984). "Glutamine: a major energy source for cultured mammalian
cells". Fed. Proc. 43: 121–125. PMID 6690331.
- ^ a
b
Eigenbrodt, E; Fister P, Reinacher M
(1985). "New perspectives on carbohydrate metabolism in tumor
cells". In: Regulation of Carbohydrate Metabolism, CRC Press,
Boca Raton, Fl 2: 141–179. ISBN
0-8493-5263-0.
- ^ a
b
Lanks, KW (1987). "End products of
glucose and glutamine metabolism by L929 cells". J. Biol.
Chem. 262: 10093–10097. PMID 3611053.
- ^ a
b
Board, M; Humm S and Newsholme EA
(1990). "Maximum activities of key enzymes of glycolysis,
glutaminolysis, pentose phosphate pathway and tricarboxylic acid
cycle in normal, neoplastic and suppressed cells". Biochem.
J. 265: 503–509. PMID 2302181.
- ^ a
b
Medina, MA; Nunez de Castro I
(1990). "Glutaminolysis and glycolysis interactions in proliferant
cells". Int. J. Biochem. 22: 681–683. doi:10.1016/0020-711X(90)90001-J. PMID 2205518.
- ^ a
b
Goossens, V; Grooten J and Fiers W
(1996). "The oxidative metabolism of glutamine. A modulator of
reactive oxygen intermediate-mediated cytotoxicity of tumor
necrosis factor in L929 fibrosarcoma cells". J. Biol.
Chem. 271: 192–196. PMID 8550558.
- ^ a
b
Mazurek, S; Michel A and Eigenbrodt
E (1997). "Effect of extracellular AMP on cell proliferation and
metabolism of breast cancer cell lines with high and low glycolytic
rates". J. Biol. Chem. 272: 4941–4952. doi:10.1074/jbc.272.8.4941. PMID 9030554.
- ^ a
b
Eigenbrodt, E; Kallinowski F, Ott M,
Mazurek S and Vaupel P (1998). "Pyruvate kinase and the interaction
of amino acid and carbohydrate metabolism in solid tumors".
Anticancer Res. 18: 3267–3274. PMID 9858894.
- ^ a
b
Piva, TJ; McEvoy-Bowe E (1998).
"Oxidation of glutamine in HeLa cells: role and control of
truncated TCA cycles in tumour mitochondria". J. Cell
Biochem. 68: 213–225. doi:10.1002/(SICI)1097-4644(19980201)68:2<213::AID-JCB8>3.0.CO;2-Y.
PMID 9443077.
- ^ Mazurek, S; Eigenbrodt E, Failing K and
Steinberg P (1999). "Alterations in the glycolytic and
glutaminolytic pathways after malignant transformation of rat liver
oval cells". J. Cell. Physiol. 181:
136–146. doi:10.1002/(SICI)1097-4652(199910)181:1<136::AID-JCP14>3.0.CO;2-T.
PMID 10457361.
- ^ a
b
Mazurek, S; Zwerschke W, Jansen-Dürr
P and Eigenbrodt E (2001). "Effects of the human papilloma virus
HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of
pyuvate kinase type M2 and the glycolytic enzyme complex".
Biochem. J. 356: 247–256. doi:10.1042/0264-6021:3560247. PMID 11336658.
- ^ a
b
Aledo, JC (2004). "Glutamine
breakdown in rapidly dividing cells: waste or investment ?".
Bioessays 26: 778–785. doi:10.1002/bies.20063. PMID 15221859.
- ^ a
b
Rossignol, R; Gilkerson R, Aggeler
R, Yamagata K, Remington SJ and Capaldi RA (2004). "Energy
substrate modulates mitochondrial structure and oxidative capacity
in cancer cells". Cancer Res. 64:
985–993. doi:10.1158/0008-5472.CAN-03-1101. PMID 14871829.
- ^ a
b
Mazurek, S (2007). "Tumor cell
energetic metabolome". In: Molecular System Bioenergetics
(Saks, V ed.) Wiley-VCH, Weinheim, Germany: 521–540. ISBN
978-3-527-31787-5.
- ^ DeBerardinis, RJ; Sayed N, Ditsworth D,
Thompson CB (2008). "Brick by brick: metabolism and tumor growth.".
Curr. Op. Gen. Dev. 18: 54–61. doi:10.1016/j.gde.2008.02.003. PMID 18387799.
- ^ Wolfrom, C; Kadhom N, Polini G, Poggi J,
Moatti N and Gautier M (1989). "Glutamine dependency of human skin
fibroblasts: modulation of hexoses". Exp. Cell Res.
183: 303–318. doi:10.1016/0014-4827(89)90391-1. PMID 2767153.
- ^
Gardner, PR; Raineri I, Epstein LB
and White CW (1995). "Superoxide radical and iron modulate
aconitase activity in mammalian cells". J. Biol. Chem.
270: 13399–13405. doi:10.1074/jbc.270.22.13399. PMID 7768942.
- ^
Kim, KH; Rodriguez AM, Carrico PM
and Melendez JA (2001). "Potential mechanisms for the inhibition of
tumor cell growth by manganese superoxide dismutase". Antioxid.
Redox. Signal. 3: 361–373. doi:10.1089/15230860152409013. PMID 11491650.
- ^
Matsuno, T; Goto I (1992).
"Glutaminase and glutamine synthetase activities in human cirrhotic
liver and hepatocellular carcinoma". Cancer Res.
52: 1192–1194. PMID 1346587.
- ^
Aledo, JC; Segura JA, Medina MA,
Alonso FJ, Nunez de Castro I and Marquez J (1994).
"Phosphate-activated glutaminase expression during tumor
development". FEBS Lett. 341: 39–42. doi:10.1016/0014-5793(94)80236-X. PMID 8137919.
- ^ a
b
Lobo, C; Ruiz-Bellido MA, Aledo JC,
Marquez J, Nunez De Castro I and Alonso FJ (2000). "Inhibition of
glutaminase expression by antisense mRNA decreases growth and
tumourigenicity of tumour cells". Biochem. J.
348: 257–261. doi:10.1042/0264-6021:3480257. PMID 10816417.
- ^
Mazurek, S; Grimm H, Oehmke M,
Weisse G, Teigelkamp S and Eigenbrodt E (2000). "Tumor M2-PK and
glutaminolytic enzymes in the metabolic shift of tumor cells".
Anticancer Res. 20: 5151–5154. PMID 11326687.
- ^
Turowski, GA; Rashid Z, Hong F,
Madri JA and Basson MD (1994). "Glutamine modulates phenotype and
stimulates proliferation in human colon cancer cell lines".
Cancer Res. 54: 5974–5980. PMID 7954430.
- ^
Spittler, A; Oehler R, Goetzinger P,
Holzer S, Reissner CM, Leutmezer J, Rath V, Wrba F, Fuegger R,
Boltz-Nitulescu G and Roth E (1997). "Low glutamine concentrations
induce phenotypical and functional differentiation of U937
myelomonocytic cells". J. Nutr. 127:
2151–2157. PMID 9349841.
- ^
Matsuno, T (1991). "Pathway of
glutamate oxidation and its regulation in HuH13 line of human
hepatoma cells". J. Cell. Physiol. 148:
290–294. doi:10.1002/jcp.1041480215. PMID 1679060.
- ^
Parlo, RA; Coleman PS (1984).
"Enhanced rate of citrate export from cholesterol-rich hepatoma
mitochondria. The truncated Krebs cycle and other metabolic
ramifications of mitochondrial membrane cholesterol". J. Biol.
Chem. 259: 9997–10003. PMID 6469976.
- ^
Mazurek, S; Grimm H, Boschek CB,
Vaupel P and Eigenbrodt E (2002). "Pyruvate kinase type M2: a
crossroad in the tumor metabolome". Brit. J. Nutr.
87: S23–S29. doi:10.1079/BJN2001455. PMID 11895152.
- ^
Eck, HP; Drings P and Dröge W
(1989). "Plasma glutamate levels, lymphocyte reactivity and death
in patients with bronchial carcinoma". J. Cancer Res. Clin.
Oncol. 115: 571–574. doi:10.1007/BF00391360. PMID 2558118.
- ^
Grimm, H; Tibell A, Norrlind B,
Blecher C, Wilker S, and Schwemmle K (1994). "Immunoregulation by
parental lipids: impact of the n-3 to n-6 fatty acid ratio". J.
Parenter. Enteral. Nutr. 18: 417–421. doi:10.1177/0148607194018005417. PMID 7815672.
- ^
Jiang, WG; Bryce RP and Hoorobin DF
(1998). "Essential fatty acids: molecular and cellular basis of
their anti-cancer action and clinical implications". Crit. Rev.
Oncol. Hematol. 27: 179–209. doi:10.1016/S1040-8428(98)00003-1. PMID 9649932.
External
links